| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Javier P Gisbert | Q37829251 |
| Paul Moayyedi | Q28039220 | ||
| Xavier Calvet | Q42788703 | ||
| Alexander C. Ford | Q37829208 | ||
| Yuhong Yuan | Q86266526 | ||
| P2093 | author name string | David Forman | |
| Grigorios I Leontiadis | |||
| Lori Fischbach | |||
| Franco Bazzoli | |||
| Giuseppina Oderda | |||
| Carlo Fallone | |||
| Khurram J Khan | |||
| Frances Tse | |||
| P2860 | cites work | Overstating the evidence: double counting in meta-analysis and related problems | Q21261918 |
| Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals | Q24197568 | ||
| Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients | Q24246267 | ||
| The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey | Q24282603 | ||
| New concepts of resistance in the treatment of Helicobacter pylori infections | Q24622513 | ||
| What is meant by intention to treat analysis? Survey of published randomised controlled trials | Q24647858 | ||
| Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report | Q24674636 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. | Q37838243 | ||
| Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori | Q37899929 | ||
| Management of Patients With Ulcer Bleeding | Q37981830 | ||
| Simpson's paradox and calculation of number needed to treat from meta-analysis | Q24801839 | ||
| Pooling data for number needed to treat: no problems for apples | Q24801867 | ||
| Meta-analysis, Simpson's paradox, and the number needed to treat | Q24801908 | ||
| Room for improvement? A survey of the methods used in systematic reviews of adverse effects | Q25256806 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis | Q28189245 | ||
| Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report | Q28203195 | ||
| Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection | Q28214073 | ||
| Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit | Q28254604 | ||
| Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report | Q28264077 | ||
| Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy | Q28296156 | ||
| A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints | Q29614902 | ||
| Systematic reviews in health care: Assessing the quality of controlled clinical trials | Q29618659 | ||
| Improving the quality of reporting of randomized controlled trials. The CONSORT statement | Q29619101 | ||
| The number needed to treat: a clinically useful measure of treatment effect | Q29619672 | ||
| What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data | Q30926358 | ||
| Individual patient data meta-analyses | Q30984226 | ||
| Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. | Q31016826 | ||
| Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. | Q31927463 | ||
| Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients | Q33185503 | ||
| Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data | Q33270075 | ||
| Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication | Q33302739 | ||
| 'Rescue' therapies for the management of Helicobacter pylori infection | Q33371187 | ||
| Systematic review: the global incidence and prevalence of peptic ulcer disease. | Q33409612 | ||
| Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group | Q33637277 | ||
| Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review. | Q33648702 | ||
| Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication | Q33735409 | ||
| First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. | Q33869371 | ||
| Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration | Q33889788 | ||
| A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection | Q33904326 | ||
| Helicobacter pylori: clinical management | Q38046421 | ||
| Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study | Q38967018 | ||
| High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication | Q39618441 | ||
| Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. | Q40731606 | ||
| Treating H. pylori shorter than one week--a real future perspective? | Q40739362 | ||
| Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology | Q41739506 | ||
| Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial | Q42267363 | ||
| Ranitidine bismuth citrate plus clarithromycin 7‐day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer | Q42680926 | ||
| Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication | Q42758929 | ||
| Response to Glanville et al.: How to identify randomized controlled trials in MEDLINE: ten years on. | Q42851769 | ||
| High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication | Q43014887 | ||
| Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia | Q43039095 | ||
| Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? | Q43231602 | ||
| Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment | Q43257289 | ||
| Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population | Q43468109 | ||
| What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis | Q43650376 | ||
| Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized contr | Q43708711 | ||
| Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication | Q43734602 | ||
| Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia | Q43787578 | ||
| Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? | Q44142867 | ||
| A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study | Q44231597 | ||
| Levofloxacin based regimens for the eradication of Helicobacter pylori | Q44240596 | ||
| Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori | Q44371256 | ||
| Use of lactoferrin for Helicobacter pylori eradication. Preliminary results | Q44408692 | ||
| Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? | Q44412317 | ||
| Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication | Q44611972 | ||
| Use of bovine lactoferrin for Helicobacter pylori eradication | Q44657327 | ||
| Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study | Q44833256 | ||
| Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? | Q44929104 | ||
| The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study | Q44931906 | ||
| Seven-day therapy for Helicobacter pylori in the United States | Q44957615 | ||
| Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment | Q45054042 | ||
| Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study | Q45074827 | ||
| Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection | Q45134181 | ||
| Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies | Q45166033 | ||
| Could increasing the duration of triple therapy be a clinically useful strategy? | Q46087175 | ||
| Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens | Q46134245 | ||
| Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea | Q46149766 | ||
| H. pylori treatment: new wine in old bottles? | Q46189063 | ||
| Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen | Q46189065 | ||
| Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori | Q46600648 | ||
| Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co‐therapy with amoxycillin and clarithromycin | Q46632463 | ||
| Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial | Q46639990 | ||
| Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate | Q46900760 | ||
| Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen | Q36883328 | ||
| The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? | Q36890505 | ||
| Evolution of Helicobacter pylori therapy from a meta-analytical perspective. | Q36996627 | ||
| Asia-Pacific consensus guidelines on gastric cancer prevention | Q37101686 | ||
| Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis | Q37358570 | ||
| Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis | Q37376383 | ||
| Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability | Q37597876 | ||
| Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection | Q37605214 | ||
| Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children | Q37618534 | ||
| Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome | Q37634300 | ||
| Prolonged Treatment Duration is Required for SuccessfulHelicobacter pyloriEradication with Proton Pump Inhibitor Triple Therapy in Canada | Q37640593 | ||
| Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition | Q37714944 | ||
| Helicobacter pylori treatment in the era of increasing antibiotic resistance | Q37762928 | ||
| Epidemiology of Helicobacter pylori infection and public health implications | Q37807473 | ||
| Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas | Q33937374 | ||
| Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. | Q33940568 | ||
| Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group | Q34033648 | ||
| Determinants of non-compliance with short term antibiotic regimens | Q34072510 | ||
| Clarithromycin for Helicobacter pylori infection | Q34182199 | ||
| Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. | Q34224762 | ||
| An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. | Q34285314 | ||
| Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer | Q34288158 | ||
| Guidelines for the management of dyspepsia | Q34453424 | ||
| Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori | Q34501295 | ||
| Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. | Q34510811 | ||
| Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? | Q34591832 | ||
| American College of Gastroenterology guideline on the management of Helicobacter pylori infection | Q34645482 | ||
| Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori | Q34651921 | ||
| Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. | Q34657365 | ||
| Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review | Q35011223 | ||
| One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer | Q35045253 | ||
| Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis | Q35129556 | ||
| How can the current strategies for Helicobacter pylori eradication therapy be improved? | Q35170309 | ||
| Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication | Q35216889 | ||
| A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori | Q35532235 | ||
| Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study | Q35761431 | ||
| 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial | Q35855301 | ||
| Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis | Q35872061 | ||
| Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. | Q35963744 | ||
| Meta-analysis: Can we mix apples and oranges? | Q35967468 | ||
| Meta-analysis: Principles and procedures | Q36247440 | ||
| American gastroenterological association technical review on the evaluation of dyspepsia | Q36312272 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey | Q36474120 | ||
| Helicobacter pylori diagnosis and management | Q36552618 | ||
| The health economics of Helicobacter pylori infection | Q36768715 | ||
| Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture | Q36817910 | ||
| A meta-analysis of the success rate of Helicobacter pylori therapy in Canada | Q36823731 | ||
| Efficacy and safety of faropenem in eradication therapy of Helicobacter pylori | Q46900776 | ||
| Improved Efficacy of Proton Pump Inhibitor – Amoxicillin – Clarithromycin Triple Therapy for Helicobacter pylori Eradication in Low Clarithromycin Resistance Areas or for Tailored Therapy | Q46981858 | ||
| Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen | Q47345605 | ||
| "No language restrictions" in database searches: what does this really mean? | Q47607529 | ||
| Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial | Q50896060 | ||
| Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori | Q52869272 | ||
| Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis | Q52938197 | ||
| Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma | Q53240014 | ||
| Update on Therapeutic Options for Helicobacter pylori-related Diseases | Q53868318 | ||
| Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study | Q54064394 | ||
| The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole | Q54090761 | ||
| Rapid eradication of Helicobacter pylori infection. | Q54181130 | ||
| Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea | Q57212456 | ||
| 2-Week Triple Therapy for Helicobacter pylori Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study | Q59509164 | ||
| Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection | Q59509397 | ||
| Long-Term Follow-Up of 1,000 Patients Cured of Helicobacter pylori Infection Following an Episode of Peptic Ulcer Bleeding | Q59509406 | ||
| ¿Siete o diez días? Estudio de coste-efectividad sobre la duración del tratamiento de la infección por H. pylori en atención primaria | Q59509657 | ||
| Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis | Q59509738 | ||
| Misleading Statistics | Q60307614 | ||
| Helicobacter pylori cagA and vacA Genotypes as Predictors of Progression of Gastric Preneoplastic Lesions: A Long-Term Follow-Up in a High-Risk Area in Spain | Q60651512 | ||
| Was It Really an “Ugly” Meta-Analysis? | Q61884904 | ||
| Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection | Q63199398 | ||
| Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months | Q71717547 | ||
| Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach | Q73495054 | ||
| Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India | Q73883848 | ||
| Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease | Q74128893 | ||
| Effectiveness of Omeprazole‐Amoxicillin‐Clarithromycin (OAC) Therapy for Helicobacter pylori Infection in a Japanese Population | Q74664544 | ||
| Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days | Q74672489 | ||
| Two‐week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing | Q74810148 | ||
| A Comparison of 10 and 14 Days of Lansoprazole Triple Therapy for Eradication of Helicobacter pylori | Q77077644 | ||
| Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis | Q77377828 | ||
| Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology | Q77709302 | ||
| Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys | Q79335179 | ||
| Treatment of Helicobacter pylori | Q80027751 | ||
| One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran | Q80653864 | ||
| Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases | Q81151547 | ||
| Small intestinal bacterial overgrowth and Helicobacter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease? | Q84261787 | ||
| Comparison of Lafutidine and Rabeprazole in 7‐day Second‐line Amoxicillin‐ and Metronidazole‐Containing Triple Therapy for Helicobacter pylori: A Pilot Study | Q84514367 | ||
| Levofloxacin-Based Three-Antibiotic Regimen for H. pylori Eradication | Q84524271 | ||
| Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days | Q84564100 | ||
| Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days? | Q85025889 | ||
| Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway | Q85234837 | ||
| P433 | issue | 12 | |
| P921 | main subject | Helicobacter pylori | Q180556 |
| Helicobacter pylori infectious disease | Q4497153 | ||
| P304 | page(s) | CD008337 | |
| P577 | publication date | 2013-12-11 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Optimum duration of regimens for Helicobacter pylori eradication |
| Q28070003 | 25 Years of Proton Pump Inhibitors: A Comprehensive Review |
| Q36425705 | A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a 'real world' setting |
| Q40378087 | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection |
| Q24188139 | Adverse events in patients taking macrolide antibiotics versus placebo for any indication |
| Q90420857 | An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment |
| Q38707430 | Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children |
| Q26777623 | Antibiotic treatment for Helicobacter pylori: Is the end coming? |
| Q35598058 | Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. |
| Q40829991 | Commentary: Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis |
| Q26796367 | Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis |
| Q89588635 | Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial |
| Q90103197 | Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial |
| Q39260796 | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial |
| Q33698340 | Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale |
| Q27000209 | Current Helicobacter pylori treatment in 2014 |
| Q39135143 | Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection |
| Q52330458 | Dealing with uncertainty in the treatment of Helicobacter pylori |
| Q36121419 | Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. |
| Q36997005 | Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice. |
| Q37656247 | Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial |
| Q93052668 | Efficacy of Vonoprazan for Helicobacter pylori Eradication |
| Q35666640 | Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers. |
| Q47158212 | First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin |
| Q33822948 | First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines |
| Q40502852 | Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance |
| Q54203358 | Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies |
| Q90179406 | Helicobacter pylori recrudescence and its influencing factors |
| Q52587043 | Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial |
| Q40102628 | Management of Helicobacter pylori Infection: What Should the Surgeon Know? |
| Q48165932 | Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment |
| Q37444220 | Optimising Antibiotic Usage to Treat Bacterial Infections. |
| Q24195105 | Optimum antibiotic doses for Helicobacter pylori eradication |
| Q58602131 | Outcomes of furazolidone- and amoxicillin-based quadruple therapy for infection and predictors of failed eradication |
| Q55898008 | Peptic ulcer disease |
| Q28084426 | Perforated peptic ulcer |
| Q49164317 | Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter pylori infection in Syrian population single-center experience |
| Q35973782 | Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection |
| Q42090635 | Recent advances in Helicobacter pylori eradication. |
| Q42682684 | Selecting the optimum first-line treatment for H. pylori eradication |
| Q37398898 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. |
| Q54261794 | Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective. |
| Q36091187 | The Indications, Applications, and Risks of Proton Pump Inhibitors |
| Q47743485 | The Resolution of Helicobacter suis-associated Gastric Lesions after Eradication Therapy |
| Q33874650 | The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication |
| Q90661571 | Top 10 Self Learning articles from 2017 |
| Q57046942 | Toward population specific and personalized treatment of Helicobacter pylori infection |
| Q39226913 | Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. |
| Q26799348 | Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis |
| Q38268663 | Use of probiotics in the fight against Helicobacter pylori |
| Q57138254 | Vitamin C: A Preventative, Therapeutic Agent Against Helicobacter pylori |
Search more.